Literature DB >> 12543531

Evaluations of health interventions in social insurance-based countries: Germany, the Netherlands, and Austria.

Claudia Wild1, Bernhard Gibis.   

Abstract

Health Technology Assessment (HTA) in social insurance-based, or so-called 'Bismarck' health care systems (Germany, Austria, and the Netherlands) has taken a different course than in either taxed-based (Sweden, Norway, United Kingdom, and Spain) or private health care systems (such as the United States). The culture of informed decisions supported by transparent and evidence-based evaluations of health interventions was hindered by the strong professional autonomy and sectoral interests in Germany and Austria for a long time. On the other hand, HTA has a long-standing tradition in the Netherlands. In all three countries sickness funds play an important role in implementing evaluations-as a policy tool-by linking reimbursement to explicit proof of effectiveness in both new and established interventions. This article focuses on the obstacles and opportunities for HTA in Germany, Austria and the Netherlands as countries with insurance-based health care systems.

Mesh:

Year:  2003        PMID: 12543531     DOI: 10.1016/s0168-8510(02)00065-9

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  3 in total

1.  On the Road to Net Zero Health Care Systems: Governance for Sustainable Health Care in the United Kingdom and Germany.

Authors:  Léa Weimann; Edda Weimann
Journal:  Int J Environ Res Public Health       Date:  2022-09-26       Impact factor: 4.614

2.  Treatment preferences in juvenile idiopathic arthritis - a comparative analysis in two health care systems.

Authors:  Boris Hugle; Johannes-Peter Haas; Susanne M Benseler
Journal:  Pediatr Rheumatol Online J       Date:  2013-01-15       Impact factor: 3.054

3.  Integrating evidence on patient preferences in healthcare policy decisions: protocol of the patient-VIP study.

Authors:  Carmen D Dirksen; Cecile Ma Utens; Manuela A Joore; Teus A van Barneveld; Bert Boer; Dunja Hh Dreesens; Hans van Laarhoven; Cees Smit; Anne M Stiggelbout; Trudy van der Weijden
Journal:  Implement Sci       Date:  2013-06-10       Impact factor: 7.327

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.